Company: NCNA
Filing Date: 2025-06-27
Form Type: 424B5
Source: 0001193125-25-151464
Chunk: 4

Company: NuCana plc
Filing Date: 2025-06-27
Form: 424B5
Chunk 4
---
-7738 is a novel anti-cancer agent that disrupts RNA polyadenylation, profoundly impacts gene
expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase 2 part of a Phase 1/2 study which is
evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with
melanoma. NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent. NUC-3373 is currently being evaluated in a Phase 1b/2 modular study (NuTide:303) of NUC-3373 in combination with
the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.

Additional Information

For additional
information related to our business and operations, please refer to the reports incorporated herein by reference, including the Annual Report on Form 20-F of NuCana plc for the year ended December 31,
2024 and the Report on Form 6-K furnished on June 2, 2025, as described under the caption “Incorporation of Documents by Reference” on page S-17 of this
prospectus supplement.

Our Corporate Information

NuCana was incorporated under the laws of England and Wales in 1997 under the name Biomed (UK) Limited, and commenced operations in 2008. On
April 28, 2008, we changed our name to NuCana BioMed Limited. On August 29, 2017, we re-registered as a public limited company and changed our name to NuCana plc. ADSs representing our ordinary
shares were admitted to trading on The Nasdaq Global Select Market on September 28, 2017. Subsequently, we transferred the listing of our ADSs to the Nasdaq Capital Market on November 9, 2023. Our ADSs are traded under the symbol
“NCNA.”

Our principal executive offices are located at 3 Lochside Way, Edinburgh, EH12 9DT, United Kingdom. Our telephone
number at this address is +44 (0)131 357 1111.

S-3

We maintain a website at
w.w.w.nucana.comto which we regularly post copies of our press releases as well